SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation I90P

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Can the Prophylactic Administration of Tranexamic Acid Reduce Blood Loss After Robotic-assisted Radical Prostatectomy? The RARPEX (Robotic Assisted Radical Prostatectomy With TranEXamic Acid) Study.

The prophylactic administration of tranexamic acid reduces blood loss during procedures at high risk of perioperative bleeding. Several studies in neurosurgery, cardiac surgery, and orthopedics confirm this finding. The aim of this study is to evaluate the effect of tranexamic acid on peri-and postoperative blood loss and incidence and severity of postoperative complications. A prospective, double-blind, randomized study is conducted to evaluate the effect on several parameters. Based on pilot study data the investigators decided to include 200 patients in the period from February 2020 to December 2021. The patients will be randomly assigned to study and control groups of 100 patients each. The minimum follow-up will be 3 months.

NCT04319614 Robotic-assisted Radical Prostatectomy Drug: Tranexamic Acid Injectable Product Drug: Placebos
MeSH:Hemorrhage

This trial was approved by the independent ethics committee at the University Hospital Hradec Kralove (registration number 201903 I90P). --- I90P ---

Primary Outcomes

Description: The drop of hemoglobin level, weighted on gram of prostate or creatinin level.

Measure: Reduction of blood loss

Time: 7 days after the procedure

Secondary Outcomes

Description: The incidence and severity of postoperative complications according to Dindo/Clavien Classification.

Measure: The risk of postoperative complications

Time: 90 days after the procedure

HPO Nodes